Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Parenthetical)

v3.19.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2019
Jun. 30, 2018
Accounts payable, related parties $ 74 $ 189
Accrued expenses, related parties $ 764 $ 789
Preferred stock, shares authorized (in shares) 1,000,000  
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 275,000,000 275,000,000
Common stock, shares issued (in shares) 19,602,458 19,602,458
Common stock, shares outstanding (in shares) 16,040,126 16,040,126
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 1,000 $ 1,000
Preferred stock, shares authorized (in shares) 6,300 6,300
Preferred stock, shares issued (in shares) 4,482 6,210
Preferred stock, shares outstanding (in shares) 4,482 6,210
Series B Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 1,000 $ 1,000
Preferred stock, shares authorized (in shares) 5,785 5,785
Preferred stock, shares issued (in shares) 5,785 5,785
Preferred stock, shares outstanding (in shares) 5,785 5,785
iBio CMO [Member]    
Preferred stock, shares authorized (in shares) 1,000,000  
Preferred stock, shares issued (in shares) 1 1
Preferred stock, shares outstanding (in shares) 1 1